ArticlePsychopharmacology2026
Acute apocynin-tandospirone derivatives (ATDs) exacerbate methamphetamine-induced hyperlocomotion in rats.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
rationaleApocynin-tandospirone derivatives (ATDs) have recently been shown to ameliorate methamphetamine (MAP)-induced behavioral abnormalities when administered chronically, presumably through antioxidant and interneuron-related mechanisms. However, their acute behavioral profile remains unclear.
objectiveIn this study, we examined whether acute ATD administration exerts antipsychotic-like effects in rats.
methodsRats received acute treatment with ATDs (A-2, A-3, A-4), atypical antipsychotics, or saline, followed by assessments of spontaneous locomotor activity and MAP-induced hyperlocomotion. Prepulse inhibition (PPI), dopamine (DA) concentrations in the medial prefrontal cortex (mPFC) and nucleus accumbens (NAC) were also measured.
resultsAcute ATD administration did not reduce spontaneous activity and failed to suppress MAP-induced hyperlocomotion. Instead, all three ATDs significantly enhanced MAP-induced locomotor responses, with A-3 showing dose-dependent potentiation. ATDs did not improve MAP-induced PPI deficits, except for a modest effect of high-dose A-3. Consistent with these behavioral outcomes, DA levels in the NAC were unchanged, and only small increases in mPFC DA were observed with A-2 and high-dose A-3.
conclusionThe results demonstrate that acute ATD administration neither suppressed MAP-induced behavioral abnormalities nor produced marked neurochemical changes, but instead enhanced MAP-induced locomotor activity, indicating a clear dissociation from their previously reported chronic effects.
Indexed as
Identifiers
41784801What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.